Site search

Clear filter
2909 results for '' found
Subscalp EEG Augmentation For Accuracy and Reliability in Epilepsy Reviews (ACTRN12625000231448)
Subscalp EEG Augmentation For Accuracy and Reliability in Epilepsy Reviews (ACTRN12625000231448)
/
Evaluating the effectiveness of sodium butyrate for treatment of anorexia nervosa in individuals aged 16 and over - an open-label proof of concept study (ACTRN12624000368538p)
Evaluating the effectiveness of sodium butyrate for treatment of anorexia nervosa in individuals aged 16 and over - an open-label proof of concept study (ACTRN12624000368538p)
/
An ALLG phase 3 randomised trial of Selinexor and Lenalidomide versus lenalidomide maintenance post Autologous stem cell transplant for patients with Newly Diagnosed multiple myeloma (SeaLAND) (A
/
Secondary Access - FEmoral or radial in Transcatheter Aortic Valve Implantation TAVI? (NCT06284837)
Secondary Access - FEmoral or radial in Transcatheter Aortic Valve Implantation TAVI? (NCT06284837)
/
A phase III randomised controlled trial and economic evaluation of Stereotactic Ablative Radiotherapy (SABR) of Comprehensive treatment of OligoMETastatic (1-3 metastases) cancer. (NCT03862911)
A phase III randomised controlled trial and economic evaluation of Stereotactic Ablative Radiotherapy (SABR) of Comprehensive treatment of OligoMETastatic (1-3 metastases) cancer. (NCT03862911)
/
Selective Serotonin Reuptake Inhibitors And Depression in Atrial Fibrillation (SAD-AF) (ACTRN12623000227695p)
Selective Serotonin Reuptake Inhibitors And Depression in Atrial Fibrillation (SAD-AF) (ACTRN12623000227695p)
/
A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of 4-10 Oligometastatic Tumors (SABR-COMET 10) (NCT03721341)
A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of 4-10 Oligometastatic Tumors (SABR-COMET 10) (NCT03721341)
/
A Phase 3, multicentre, randomized, double-blind, placebo controlled study of oral ozanimod as maintenance therapy for moderately to severely active Crohn’s disease (RPC01-3203) (NCT03464097)
A Phase 3, multicentre, randomized, double-blind, placebo controlled study of oral ozanimod as maintenance therapy for moderately to severely active Crohn’s disease (RPC01-3203) (NCT03464097)
/
A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease (Celgene 3202) (NCT03440385)
A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease (Celgene 3202) (NCT03440385)
/
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease (NCT03467958)
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease (NCT03467958)
/
31 32 33 34 35